Entrada Therapeutics (TRDA) Competitors

Entrada Therapeutics (NASDAQ:TRDA) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Which has better valuation & earnings, TRDA or SDGR?

Schrödinger has higher revenue and earnings than Entrada Therapeutics. Schrödinger is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$129.01M	3.78	-$6.68M	$1.59	8.20
Schrödinger	$216.67M	7.61	$40.72M	-$2.34	-9.68

Is TRDA or SDGR more profitable?

Entrada Therapeutics has a net margin of 25.53% compared to Schrödinger's net margin of -91.84%. Entrada Therapeutics' return on equity of 16.11% beat Schrödinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	25.53%	16.11%	10.39%
Schrödinger	-91.84%	-35.77%	-24.51%

Do insiders & institutionals have more ownership in TRDA or SDGR?

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 79.1% of Schrödinger shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by insiders. Comparatively, 8.6% of Schrödinger shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate TRDA or SDGR?

Entrada Therapeutics currently has a consensus price target of $25.67, suggesting a potential upside of 96.83%. Schrödinger has a consensus price target of $32.11, suggesting a potential upside of 41.83%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Entrada Therapeutics is more favorable than Schrödinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Schrödinger	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80

Which has more volatility and risk, TRDA or SDGR?

Entrada Therapeutics has a beta of -0.17, suggesting that its stock price is 117% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.

Does the media refer more to TRDA or SDGR?

In the previous week, Schrödinger had 3 more articles in the media than Entrada Therapeutics. MarketBeat recorded 4 mentions for Schrödinger and 1 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.59 beat Schrödinger's score of 0.68 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Schrödinger	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer TRDA or SDGR?

Schrödinger received 35 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 82.61% of users gave Entrada Therapeutics an outperform vote while only 57.45% of users gave Schrödinger an outperform vote.

Company	Underperform	Outperform
Entrada Therapeutics	Outperform Votes 19 82.61%	Underperform Votes 4 17.39%
Schrödinger	Outperform Votes 54 57.45%	Underperform Votes 40 42.55%

Summary

Entrada Therapeutics beats Schrödinger on 10 of the 18 factors compared between the two stocks.